Katherine M. Krajewski

Dana-Farber Brigham Cancer Center — United States

Medicine · Health Sciences

46h-index6.6kcitations185works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(61), Renal and related cancers(23), Medical Imaging and Pathology Studies(22), Sarcoma Diagnosis and Treatment(18), Radiopharmaceutical Chemistry and Applications(18)

Publications183 total

Network Radiology as a New Paradigm in Radiology Practice: Recent Insights From Integrated Health Systems in the United States
Korean Journal of Radiology·2026Open Access
Baseline radiological tumor burden to sub-stratify IMDC risk groups in metastatic renal cell carcinoma treated with first-line therapy: A post hoc analysis from a randomized phase III trial.
Journal of Clinical Oncology·2025
Navigating advanced renal cell carcinoma in the era of artificial intelligence
Cancer Imaging·2025· 6 citedOpen Access
Metabolic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Journal of Clinical Oncology·2025· 1 cited
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Nature Cancer·2025· 17 citedOpen Access
State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer
Korean Journal of Radiology·2025Open Access
46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens
The Oncologist·2024Open Access
Insights into Renal Cell Carcinoma with Novel Imaging Approaches
Hematology/Oncology Clinics of North America·2023· 6 cited
Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
2023Open Access
Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
2023Open Access
Supplementary Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
2023Open Access
Supplementary Data from Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
2023Open Access
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
2023Open Access
Data from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
Supplementary Table, Supplementary Figure Legends from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
Figure S3 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
2023Open Access
Supplementary Table, Supplementary Figure Legends from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
Figure S4 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
Figure S2 from Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Nikhil H. Ramaiya(38), Jyothi P. Jagannathan(28), Atul B. Shinagare(20), Toni K. Choueiri(13), Sree Harsha Tirumani(12), Stephanie A. Howard(9), Jason L. Hornick(8), Kyung Won Kim(7), Mizuki Nishino(6), Kevin O′Regan(6), Katherine Zukotynski(6), Angela Giardino(5), Joaquim Bellmunt(4), Guillermo de Velasco(4), Laurence Albigès(4), David F. McDermott(4), Kevin N. O’Regan(4), Annick D. Van den Abbeele(4), Wanling Xie(3), Dominick Bossé(3)